Next Article in Journal
Phosphonic Acid Analogues of Phenylglycine as Inhibitors of Aminopeptidases: Comparison of Porcine Aminopeptidase N, Bovine Leucine Aminopeptidase, Tomato Acidic Leucine Aminopeptidase and Aminopeptidase from Barley Seeds
Next Article in Special Issue
What Is Next in This “Age” of Heme-Driven Pathology and Protection by Hemopexin? An Update and Links with Iron
Previous Article in Journal
Metal-Based Complexes as Pharmaceuticals for Molecular Imaging of the Liver
Previous Article in Special Issue
Twenty Years of Ferroportin Disease: A Review or An Update of Published Clinical, Biochemical, Molecular, and Functional Features
Open AccessReview

The Efficacy of Iron Chelators for Removing Iron from Specific Brain Regions and the Pituitary—Ironing out the Brain

1
Faculty of Science, Universite catholique de Louvain, 1348 Louvain-la-Neuve, Belgium
2
Division of Brain Sciences, Imperial College, London W12 ONN, UK
3
Institute of Pharmaceutical Science, King’s College London, London SE1 9NH, UK
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2019, 12(3), 138; https://doi.org/10.3390/ph12030138
Received: 23 July 2019 / Revised: 10 September 2019 / Accepted: 11 September 2019 / Published: 17 September 2019
(This article belongs to the Special Issue Iron as Therapeutic Targets in Human Diseases)
Iron chelation therapy, either subcutaneous or orally administered, has been used successfully in various clinical conditions. The removal of excess iron from various tissues, e.g., the liver spleen, heart, and the pituitary, in beta thalassemia patients, has become an essential therapy to prolong life. More recently, the use of deferiprone to chelate iron from various brain regions in Parkinson’s Disease and Friederich’s Ataxia has yielded encouraging results, although the side effects, in <2% of Parkinson’s Disease(PD) patients, have limited its long-term use. A new class of hydroxpyridinones has recently been synthesised, which showed no adverse effects in preliminary trials. A vital question remaining is whether inflammation may influence chelation efficacy, with a recent study suggesting that high levels of inflammation may diminish the ability of the chelator to bind the excess iron. View Full-Text
Keywords: iron; chelation; neurodegenerative diseases; pituitary; brain iron; chelation; neurodegenerative diseases; pituitary; brain
Show Figures

Figure 1

MDPI and ACS Style

Crichton, R.R.; Ward, R.J.; Hider, R.C. The Efficacy of Iron Chelators for Removing Iron from Specific Brain Regions and the Pituitary—Ironing out the Brain. Pharmaceuticals 2019, 12, 138.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop